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the proliferation of leukemic blasts, nor in the protection from
apoptosis, despite several observations that have involved MIF
in protecting a variety of cell types from apoptosis. From a more
practical point of view, the MIF-173 G/C polymorphism, as well
as other previously investigated genetic variants, does not
contribute to prednisone poor response in vivo in childhood
acute lymphoblastic leukemia. Alternative biologic markers are
worth to be investigated in such patients.
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TO THE EDITOR
The human large tumor suppressor 2 (LATS2/KPM) gene, which
encodes a novel serine/threonine kinase, has been mapped onto
chromosome 13q11–12, a hot spot region for loss of hetero-
zygosity in primary cancers, suggesting that LATS2 might function
as a tumor suppressor gene.1 Although chromosome aberrations
involving 13q12 have been described in a minority (3–6%) of
acute lymphoblastic leukemia (ALL) patients and frequently occur
as secondary events after relapse, these patients show an
extremely poor outcome.2 DNA methylation is an essential
mechanism for the regulation of gene expression in mammalian
cells. The promoter of the LATS2 gene contains a defined CpG
island and its hypermethylation has been recently associated to an
aggressive phenotype in breast cancers.3 All these facts led us to
analyze the potential role of the inappropriate expression/
promoter hypermethylation of the LATS2 gene in a number of
cell lines and primary cells from ALL patients.
Four human precursor-B (MY, TOM-1, NALM-20 and TANOUE)
and three T cell (JURKAT, LOUCY and MOLT-4) ALL cell lines
Table 1 Distribution of the MIF-173 genotypes in controls and in 151 patients with childhood acute lymphoblastic leukemia, overall and
according to steroid response
MIF-173 Controls
N (%)
Acute lymphoblastic
leukemia N (%)
Acute lymphoblastic
leukemia & PPR N (%)
Acute lymphoblastic
leukemia & PGR N (%)
G/G 277 (78.4) 117 (77.5) 59 (76.6) 58 (78.4)
C/G 76 (21.4) 34 (22.5) 18 (23.4) 16 (21.6)
C/C 2 (0.6) 0 0 0
Total 355 (100) 151 (100) 77 (100) 74 (100)
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were used for experiments. Bone marrow samples were collected
after an acquisition of informed consent from 101 consecutive
patients (65 male; 36 female), who were diagnosed with de novo
ALL between December 1996 and August 2004. The median age
at diagnosis in the study population as a whole was 20 years
(range, 0.7–72 years). Of these patients, 54 were children (median
age, 7 years; range, 0.7–14) and 47 presented adult ALL (median
age, 35 years; range, 15–72). Patients were studied at the time of
initial diagnosis and were risk-stratified according to the therapeu-
tic protocols of the PETHEMA Spanish Study Group. For statistical
analyses, children were also grouped according to the National
Cancer Institute (NCI) risk-classification criteria. In all, 24 patients
relapsed. Eight patients received stem-cell transplantation (two
autologous, six allogeneic). There are 68 patients currently alive.
Aberrant promoter methylation of LATS2 gene (GeneBank:
26524) was determined by methylation specific PCR (MSP)
method. Primer sequences of LATS2 for the unmethylated
reaction were: forward (50-GGTGTTTTAGATTTGAAAGGTTGT
AGT-30) and reverse (50-AAAAAACTAATTAACCCATAAAACA
AT-30). Primer sequences for the methylated reaction were:
forward (50-GTTTTAGATTCGAAAGGTCGTAGC-30) and reverse
(50-AAAACTAATTAACCCGTAAAACGAT-30). DNA from mono-
nuclear marrow cells (n¼ 20) from healthy donors were used as
negative controls for methylation-specific assays.
RNA from mononuclear marrow cells was used for quantita-
tive real-time PCR (qrt-PCR) for LATS2 mRNA expression.
Reverse transcription was performed on 1mg total RNA with
random hexamers as reaction primer. Qrt-PCR was performed in
a rapid fluorescent thermal cycler (LightCycler2.0, Roche).
Primer set was specific for the LATS2 gene (GeneBank:
NM_014572; forward LATS2 exon 5, 50- GTAGGACGCAAACG
AAT-30; reverse LATS2 exon 7, 50-CAGAAGTGAACCGGCA-30).
Amplification of Abelson (ABL1) gene transcripts was performed
to assess RNA integrity and as reference gene. In order to reduce
the variation between different assays and samples, a procedure
based on the relative quantification of target genes vs their
controls in relation to the reference gene was used. Calculations
were automatically performed by LightCycler software (Real-
Quant, version 1.0, Roche). The selected control was the
mononuclear cells of bone marrow specimen from a healthy
donor. It was considered as 100% expression.
To determine the cutoff point for altered LATS2 expression in
ALL patients and cell lines, the value for LATS2 was firstly
determined in 15 bone marrow samples from healthy donors. In
these individuals, LATS2 expression fell between 149 and 78%
(mean: 104721%). A LATS2 value equal or below 40%
(determined as the mean minor 3 s.d.) was chosen to
define underexpression of LATS2 in ALL mRNA samples. We
found a strong reduction of LATS2 mRNA in all the B/T-cell
precursor ALL cell lines tested (mean, 1.4%; range, 0–6%)
and also in 35% of diagnostic ALL samples (mean, 15.7%;
range, 0–40%).
CpG island of the LATS2 promoter was revealed to be highly
methylated in five ALL cell lines lacking LATS2 expression (TOM-
1, NALM-20, MY, TANOUE and LOUCY), whereas JURKAT and
MOLT-4 cell lines showed an unmethylated pattern despite
expressing low LATS2 transcript levels (Figure 1a). Exposure to
4mM concentration of the demethylating agent 5-Aza-20-deox-
ycytidine restored the expression of LATS2 mRNA in the MY,
NALM-20, TOM-1, TANOUE and LOUCY ALL cell lines
indicating that hypermethylation is a major mechanism by which
LATS2 expression is silenced in ALL cells (Figure 1b).
LATS2 methylation status was also studied in 66 ALL patients
enrolled in this study in which DNA samples were available. A
methylated promoter was observed in 16 of them (24%) and in
13 of these cases (81.2%), methylation was associated with
decreased LATS2 expression levels. In contrast, low expression
was detected in only 11 (8 B-ALL and 3 T-ALL) of 50 ALL with
unmethylated pattern (22%). This result indicated that CpG
methylation within LATS2 promoter strongly correlated with
decreased constitutive expression of LATS2 in ALL cells
(Po0.001).
Low expression of LATS2 was detected at diagnosis in 35%
(35 out of 101) of ALL patients with adult or childhood ALL
belonging to all the FAB subtypes. Reduced levels of LATS2
mRNA were more frequently observed among adult ALL patients
(22 out of 47, 47%) than in children (13 out of 54, 24%)
(P¼ 0.01). Moreover, correlating LATS2 expression with pre-
treatment risk groups, we detected a significant association
between reduced LATS2 expression and high-risk ALL children
assessed by the NCI scoring system (P¼ 0.004) and also with
two poor-risk subgroups defined by the presence of BCR-ABL
fusion gene (P¼ 0.05) and T-cell lineage ALL (Po0.001).
Complete remission (CR) rates of patients with normal and
low LATS2 gene expression were 97 and 91%, respectively,
suggesting that expression of the LATS2 gene did not correlate
with response to remission induction therapy.
As show in Table 1 patients with low expression had higher
relapse (53 vs 12%, Po0.001) and mortality (69 vs 14%,
Po0.001) rates than normal expressing patients. The adverse
prognostic impact of low LATS-2 expression on relapse and
mortality remained after adjustment for age, WBC count,
immunophenotype, NCI risk groups and cytogenetics.
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Figure 1 Methylation status and expression of LATS2 in ALL cell
lines. (a) MSP analysis of CpG island within LATS2 promoter in seven
ALL cell lines. Positive control represents methylated genomic DNA;
negative control indicates unmethylated control (bone marrow
mononuclear cells from a healthy donor). Promoter methylation is
observed in MY, TOM-1, NALM-20, LOUCY and TANOUE cell lines.
(b) Qrt-PCR analysis of LATS2 mRNA before (white bar) and after
(black bar) treatment with 5-Aza-20-deoxycytidine in the ALL cell lines
shown above. Expression of LATS2 in all the methylated cell lines (MY,
TOM-1, NALM-20, LOUCY and TANOUE) is reverted by 5-Aza-
20-deoxycytidine. Conversely, JURKAT and MOLT-4 cell lines, which
were not methylated at LATS2 promoter, show no changes in LATS2
expression after the demethylating treatment.
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Table 1 Relapse and mortality for patients who exhibited low levels of LATS2 expression and the equivalent data for patients with normal
LATS2 gene according to different characteristics
Relapse Exitus
Low expression
% (N¼ 30)
Normal expression
% (N¼ 64)
P Low expression
% (N¼ 35)
Normal expression
% (N¼ 66)
P
All patients (N¼ 101) 53 12 o0.001 69 14 o0.001
Age
Younger than 15 years (N¼ 54) 50 7 0.001 46 7 0.001
Older than 15 years (N¼ 47) 56 22 0.02 82 24 o0.001
WBC
Below 50109/l (N¼ 73) 40 10 0.004 65 10 o0.001
Above 50 109/l (N¼28) 80 20 0.003 75 25 0.009
Blast lineage
B lineage (N¼ 81) 56 12 o0.001 70 13 o0.001
T lineage (N¼ 20) 50 20 0.2 67 20 0.06
NCI risk groups (children)
Standard (N¼ 31) 33 7 0.1 33 7 0.1
Poor (N¼ 23) 56 8 0.01 50 8 0.02
Cytogenetics/molecular abnormalities
BCR-ABL (N¼14) 57 75 NS 100 83 NS
TEL-AML1 (N¼15) 50 0 0.008 0 0 NS
WBC¼ indicates white blood count;
NCI¼National Cancer Institute.
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Figure 2 Kaplan–Meier survival function according to LATS2 expression levels. DFS (panel a) and OS (panel b) curves for childhood. Adult
DFS (panel c) and OS (panel d).
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We analyzed the disease-free survival (DFS) and overall
survival (OS) according to LATS2 expression. Among children,
the 6-year DFS was 80% for normal expressing group and
41.6% for low expressing group (P¼ 0.0005) (Figure 2a). Among
adult ALL patients, the 2-year DFS was 76% for patients with
normal LATS-2 levels and 0% for patients with low LATS-2
levels (Po0.0001) (Figure 2c). Significant differences were
observed in the actuarial OS among patients with normal and
low levels of LATS-2 in the separate analyses of children (85.6 vs
36.7%, respectively, P¼ 0.0003; Figure 2b) and adults (63.3 vs
0%, respectively, P¼ 0.0001; Figure 2d).
A multivariate analysis of potential prognostic factors
demonstrated that expression of the LATS2 gene was the most
important prognostic factor in predicting DFS (Po0.0001) and
OS (Po0.0001) in the global series and also in both childhood
(P¼ 0.002 in DFS and OS) and adult ALL (Po0.0001 in DFS and
P¼ 0.003 in OS). Only factors like BCR-ABL in adults (P¼ 0.02
in DFS and P¼ 0.04 in OS) and hyperleucocytosis in children
(P¼ 0.05 in DFS) reached also statistical significance in the
multivariate analysis.
In this study we have identified, for the first time, the LATS2
gene as a target gene for epigenetic regulation in ALL. Low
expression of LATS2 gene was associated with methylation of
the LATS2 promoter region in leukemic cells. Although
methylation of the LATS2 promoter was significantly associated
with decrease of LATS2 expression, some discordant values
were recorded. A minority of patients (n¼ 3) who expressed
normal levels of LATS2 also showed methylation of the gene. All
these patients showed levels (42, 48 and 68%) near to the cutoff
point (40%) chosen to define underexpression in this study.
Although the presence of contaminating RNA from normal bone
marrow cells cannot be ruled out in these cases, they also may
indicate a partial methylation state of the promoter region.
Moreover, our study cannot exclude other potential mechanisms
of LATS2 downregulation since in 11 of our ALL patients and
also in JURKAT and MOLT-4 cell lines there were no apparent
methylation despite loss of LATS2 expression.
What is the functional significance underlying the down-
regulation of LATS2 in ALL? LATS2 is a putative tumor
suppressor gene with three key functions: it negatively regulates
the cell cycle by controlling G1-S and/or G2-M transition,4,5
induces apoptosis through downregulating antiapoptotic pro-
teins, Bcl-2 and Bcl-x(L),6 and plays an essential role in the
integrity of processes that govern centrosome duplication,
maintenance of mitotic fidelity and genomic stability.7 In this
study, decrease of LATS2 expression was found to be correlated
with several dismal prognostic features in ALL patients: low
expression of LATS2 gene was more frequently observed among
classical high-risk ALL groups (adults, T-cell phenotype, NCI
poor risk and the presence of BCR-ABL fusion gene) and was
also significatively and independently associated with a shorter
DFS and OS in both adult and childhood ALL. These findings,
together with the general expression of LATS2 in normal bone
marrow, the emerging role of the LATS2 gene in other types of
human cancer (ie, prostate and breast carcinoma),3,8 and the
confirmed role for LATS2 gene in mechanisms related to cellular
homeostasis, such as apoptosis, genomic integrity and cell cycle
regulation are supportive of LATS2 inactivation contributing
directly to the clinical behavior of ALL
In conclusion, our results strongly suggest that downregula-
tion of LATS2 expression mainly by aberrant promoter
methylation is a frequent event in ALL and plays a role in the
clinical outcome of the disease.
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